Inhibitor Therapeutics (INTI) 10-Q 12 Aug 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Aug. 12, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Document Quarterly Report	true
Document Transition Report	false
Entity Registrant Name	Inhibitor Therapeutics, Inc.
Entity File Number	001-13467
Entity Central Index Key	0001042418
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	30-0793665
Entity Address, Address Line One	449 South 12th Street
Entity Address, Address Line Two	Unit 1705
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33602
City Area Code	888
Local Phone Number	841-6811
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		376,858,323

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 24,945	$ 30,626
Prepaid expenses	13,572	28,158
Total current assets	38,517	58,784
Total assets	38,517	58,784
Current liabilities:
Accounts payable	311,878	279,842
Dividends payable, related party	200,002	100,823
Note payable, related party	331,000	231,000
Interest payable, related party	27,139	14,965
Other liabilities	65,000	53,000
Total current liabilities	935,019	679,630
Deferred revenue, related party	3,000,000	3,000,000
Total liabilities	3,935,019	3,679,630
Commitments and contingencies (note 7)
Stockholders' deficit:
Common stock, $0.0001 par value; 500,000,000 shares authorized; 376,858,323 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	37,686	37,686
Additional paid-in capital	50,051,711	50,051,711
Accumulated deficit	(57,946,765)	(57,671,109)
Total stockholders' deficit	(3,896,502)	(3,620,846)
Total liabilities and stockholders' deficit	38,517	58,784
Series A Preferred Stock [Member]
Stockholders' deficit:
Preferred stock	0	0
Series B Convertible, Redeemable, Preferred Stock [Member]
Stockholders' deficit:
Preferred stock	3,960,866	3,960,866
Undesignated Preferred Stock [Member]
Stockholders' deficit:
Preferred stock	$ 0	$ 0

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	2,253,623	2,253,623
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	500,000,000	500,000,000
Common Stock, shares issued	376,858,323	376,858,323
Common Stock, shares outstanding	376,858,323	376,858,323
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Convertible, Redeemable, Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	7,246,377	7,246,377
Preferred stock, shares issued	5,797,102	5,797,102
Preferred stock, shares outstanding	5,797,102	5,797,102

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues [Abstract]
Revenues:	$ 0	$ 0	$ 0	$ 0
Expenses:
Research and development	6,150	950	6,150	4,830
General and administrative	64,654	61,685	158,154	225,558
Total expenses	70,804	62,635	164,304	230,388
Loss from operations	(70,804)	(62,635)	(164,304)	(230,388)
Interest expense, related party	(6,763)	(3,547)	(12,173)	(5,232)
Gain on loan forgiveness	0	0	0	41,600
Net loss	(77,567)	(66,182)	(176,477)	(194,020)
Preferred stock dividend	(49,863)	(49,863)	(99,178)	(99,178)
Net loss applicable to common stockholders	$ (127,430)	$ (116,045)	$ (275,655)	$ (293,198)
Basic net loss applicable to common stockholders per share	$ 0	$ 0	$ 0	$ 0
Diluted net loss applicable to common stockholders per share	$ 0	$ 0	$ 0	$ 0
Weighted average common stock shares outstanding – basic	376,858,323	375,876,361	376,858,323	375,703,064
Weighted average common stock shares outstanding – diluted	376,858,323	375,876,361	376,858,323	375,703,064

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Total	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2020	$ (3,360,203)	$ 3,960,866	$ 37,364	$ 49,814,043	$ (57,172,476)
Beginning balance, shares at Dec. 31, 2020		5,797,102	373,635,873
Common shares issued in payment of Preferred Stock dividend, related party	100,822		$ 224	100,598
Common shares issued in payment of Preferred Stock dividend, related party, Shares			2,240,488
Stock based compensation	37,990			37,990
Preferred stock dividends, related party	(49,315)				(49,315)
Net loss	(127,838)				(127,838)
Ending balance at Mar. 31, 2021	(3,398,544)	$ 3,960,866	$ 37,588	49,952,631	(57,349,629)
Ending balance, shares at Mar. 31, 2021		5,797,102	375,876,361
Beginning balance at Dec. 31, 2020	(3,360,203)	$ 3,960,866	$ 37,364	49,814,043	(57,172,476)
Beginning balance, shares at Dec. 31, 2020		5,797,102	373,635,873
Net loss	(194,020)
Ending balance at Jun. 30, 2021	(3,514,589)	$ 3,960,866	$ 37,588	49,952,631	(57,465,674)
Ending balance, shares at Jun. 30, 2021		5,797,102	375,876,361
Beginning balance at Mar. 31, 2021	(3,398,544)	$ 3,960,866	$ 37,588	49,952,631	(57,349,629)
Beginning balance, shares at Mar. 31, 2021		5,797,102	375,876,361
Preferred stock dividends, related party	(49,863)				(49,863)
Net loss	(66,182)				(66,182)
Ending balance at Jun. 30, 2021	(3,514,589)	$ 3,960,866	$ 37,588	49,952,631	(57,465,674)
Ending balance, shares at Jun. 30, 2021		5,797,102	375,876,361
Beginning balance at Dec. 31, 2021	(3,620,846)	$ 3,960,866	$ 37,686	50,051,711	(57,671,109)
Beginning balance, shares at Dec. 31, 2021		5,797,102	376,858,323
Preferred stock dividends, related party	(49,315)				(49,315)
Net loss	(98,910)				(98,910)
Ending balance at Mar. 31, 2022	(3,769,071)	$ 3,960,866	$ 37,868	50,051,711	(57,819,334)
Ending balance, shares at Mar. 31, 2022		5,797,102	376,858,323
Beginning balance at Dec. 31, 2021	(3,620,846)	$ 3,960,866	$ 37,686	50,051,711	(57,671,109)
Beginning balance, shares at Dec. 31, 2021		5,797,102	376,858,323
Net loss	(176,477)
Ending balance at Jun. 30, 2022	(3,896,502)	$ 3,960,866	$ 37,868	50,051,711	(57,946,765)
Ending balance, shares at Jun. 30, 2022		5,797,102	376,858,323
Beginning balance at Mar. 31, 2022	(3,769,071)	$ 3,960,866	$ 37,868	50,051,711	(57,819,334)
Beginning balance, shares at Mar. 31, 2022		5,797,102	376,858,323
Preferred stock dividends, related party	(49,864)				(49,864)
Net loss	(77,567)				(77,567)
Ending balance at Jun. 30, 2022	$ (3,896,502)	$ 3,960,866	$ 37,868	$ 50,051,711	$ (57,946,765)
Ending balance, shares at Jun. 30, 2022		5,797,102	376,858,323

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net loss	$ (176,477)	$ (194,020)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	0	37,990
Gain on loan forgiveness	0	(41,600)
Changes in assets and liabilities:
Prepaid expenses and other assets	14,586	13,896
Accounts payable and other current liabilities	56,210	26,391
Net cash used in operating activities	(105,681)	(157,343)
Financing activities:
Proceeds from note payable, related party	100,000	176,000
Net cash provided by financing activities	100,000	176,000
Net change in cash and cash equivalents	(5,681)	18,657
Cash and cash equivalents at beginning of period	30,626	75,059
Cash and cash equivalents at end of period	24,945	93,716
Non-cash financing activities:
Issuance of common stock for payment of Preferred Stock dividend	0	100,822
Accrued, but unpaid dividends	$ 99,178	$ 99,178

Corporate overview

Corporate overview	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Corporate overview	1. Corporate overview: Overview The accompanying unaudited condensed financial statements of Inhibitor Therapeutics, Inc., a Delaware corporation (the “Company”, “INTI”, “we”, “us” or similar terminology), have been prepared by the Company without audit. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of June 30, 2022, and for all periods presented, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulations. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2021, which are included in the Company’s Annual Report on Form 10-K As used herein, the term “Common Stock” means the Company’s common stock, $0.0001 par value per share. The results of operations for the three-month and six-month Nature of the Business and Background The Company is a pharmaceutical development company that is focused on developing and ultimately commercializing innovative therapeutics for patients with certain cancers and certain non-cancerous The Company’s current primary focus (assuming normal operations are able to recommence) is expected to be on the development of therapies initially for prostate and lung cancer in the U.S. market utilizing SUBA-Itraconazole, a patented, oral formulation of the drug itraconazole currently approved by the U.S. Food and Drug Administration (“FDA”) and marketed as an anti-fungal, to non-cancerous The Company demonstrated in its previous Phase 2b trial for SUBA-Itraconazole BCCNS that the dosing of oral capsules of SUBA-Itraconazole affects the Hedgehog signaling pathway, a major regulator of many fundamental cellular processes, which, in turn, can impact the development and growth of cancers such as basal cell carcinoma. Itraconazole has been approved by the FDA for, and has been extensively used to, treat fungal infections and has an extensive history of safe and effective use in humans. The Company has developed, optioned and licensed intellectual property and know-how Manufacturing and Product Supply and Relationship with Mayne Pharma The Company does not have any production facilities or manufacturing personnel. The Third Amended SLA provides for the supply to the Company of specially formulated capsules of SUBA-Itraconazole, manufactured by Mayne Pharma under cGMP (current good manufacturing practice) standards, for use by the Company in its clinical trials and for the future commercial supply following FDA approvals, if obtained. Pursuant to the Third Amended SLA, Mayne Pharma is obligated to supply the Company with its patented formulation of SUBA-Itraconazole in a particular oral dose formulation for the treatment of human patients with certain cancers and non-cancerous

Liquidity and management's plan

Liquidity and management's plans	6 Months Ended
	Jun. 30, 2022
Text Block [Abstract]
Liquidity and management's plans	2. Liquidity and management’s plans: The Company had cash and cash equivalents of $24,945 as of June 30, 2022. Based on the Company’s current operational plan and budget and additional funds provided by Mayne Pharma in July 2022, the Company expects that it has sufficient cash to manage its business into October of 2022, although this estimation assumes the Company does not begin any clinical trials, acquire other drug development opportunities or otherwise face unexpected events, costs or contingencies, any of which could affect the Company’s cash requirements. Available resources may be consumed more rapidly than anticipated, resulting in the need for additional funding. As such time as the Company is able to recommence its research and development activities, significant additional funding will be required to advance the Company’s business. The Company will consider financing these and other corporate efforts and its working capital needs primarily through: • proceeds from public and private financings (including most recently, financing from the Company’s majority shareholder, Mayne Pharma) and, potentially, from other strategic transactions; • royalty revenue from Mayne Pharma from sales of SUBA-Itraconazole BCCNS upon and assuming approval by FDA (after earned royalties have been applied to any royalties advanced under Third Amended SLA, although it is uncertain if and when such FDA approval will be obtained); • proceeds from the exercise of outstanding warrants previously issued in private financings (including, potentially, warrants held by the Company’s majority shareholder, Mayne Pharma); • potential partnerships with other pharmaceutical companies to assist in the supply, manufacturing and distribution of products for which the Company would expect to receive upfront milestone and royalty payments; • potential licensing and joint venture arrangements with third parties, including other pharmaceutical companies where we would receive funding based on out-licensing • government or private foundation grants or loans which would be awarded to the Company to further develop the Company’s current and future therapies, or government payroll protection or similar programs available as a result of the novel coronavirus outbreak. However, there is a significant risk that none of these plans will be implemented in a manner necessary to sustain the Company beyond October of 2022, and that the Company will be unable to obtain additional financing when needed on commercially reasonable terms, if at all. In particular, the Company is presently subject to shareholder litigation (see Note 7 – Legal Proceedings). The existence of the Action and the P each as defined in Note 7) and the uncertainty surrounding their outcome has impeded the Company’s ability to secure additional funding and may continue to do so for so long as the outcome of the Action and the P As a result of the foregoing circumstances, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements included herein do not include any adjustments relating to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies: Estimates The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Revenue Recognition The Company currently has no ongoing source of revenues. Miscellaneous income, including interest, is recognized when earned by the Company. Deferred revenue represents cash received for royalties in advance of being earned. Such payments are reflected as deferred revenue until recognized under the Company’s revenue recognition policy. Deferred revenue would be classified as current if management believes the Company will be able to recognize the deferred amount as revenue within twelve months of the balance sheet date. Deferred revenue will be recognized when the product is sold and the royalty is earned. Since all deferred revenue is related to the SUBA-Itraconazole BCCNS product which is yet to be approved by FDA, the Company has determined that 100% of the advances of the royalty received by Mayne Pharma should be classified as non-current. Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts which is $250,000 for substantially all depository accounts. As of June 30, 2022, the Company had no excess of the amount covered by Federal Deposit Insurance Corporation. Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company and purchased in-process Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employees Income Taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. These differences occur primarily in share-based compensation. Recent accounting pronouncements: Management has considered all recent accounting pronouncements issued, but not effective, and does not believe that they will have a material impact on the Company’s financial statements.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2022
Notes Payable [Abstract]
Notes Payable	4. Notes Payable: On May 3, 2020, the Company received loan proceeds of $41,600 (the “PPP Loan”) from Citibank, N.A. pursuant to the Small Business Administration (“SBA”) Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The PPP Loan, which was in the form of a promissory note dated May 2, 2020, was to mature on May 2, 2022 with an interest rate of 1% per annum. No payments were made under the loan. The Company was entitled to prepay the PPP Loan at any time prior to maturity with no prepayment penalties. The promissory note contained events of default and other provisions customary for a loan of this type. The loan was forgiven by the SBA under the terms of the CARES Act on March 31, 2021. Under the terms of the CARES Act, PPP loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The Company used the loan proceeds for purposes consistent with the CARES Act.

Mayne Term Debt Facility

Mayne Term Debt Facility	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Mayne Term Debt Facility	5. Mayne Term Debt Facility On December 12, 2020, the Company and Mayne Pharma entered into a letter agreement for a term debt facility (the “Loan Agreement”) pursuant to which Mayne Pharma provided an aggregate $231,000 credit facility to the Company (the “Facility”). The Facility bears interest at the rate equal to the interest rate tied to the US Bank Prime Rate plus 5.00% (the “Interest Rate”) with a maturity date of twenty four (24) months from the date of the first drawdown (the “Maturity Date”). The Interest Rate shall be adjusted for each drawdown on the Facility in accordance with changes in the monthly average of the US Bank Prime Rate, as reported in the Federal Reserve Statistical Release H .15 for the month preceding the week in which the Company shall make a drawdown against the Facility. Proceeds drawn from the Facility will be used by the Company for general working capital and corporate purposes. The Facility was available to the Company as follows: (i) $81,000 may be drawn upon request at any time in the first annual quarter of the Facility starting December 14, 2020 ($55,000 was requested and was outstanding at December 31, 2020) and (ii) so long as there is no event of default and Mayne Pharma does not give notice in its discretion 30 days before the start of a quarter that it is discontinuing the funding, $75,000 may be drawn in the second and third annual quarters of the Facility, respectively. Any drawdown by the Company must equal or exceed $25,000. The Company shall have one twelve month repayment free advance period from its first drawdown on the Facility. Each other advance on the Facility will be amortized over twelve equal monthly payments of principal plus interest. No premium is payable in the event that the Company pays all principal, interest and other outstanding amounts due to Mayne Pharma prior to the Maturity Date. The Facility is unsecured, contains no financial covenants, requires no guarantees and is not accompanied by any equity component. The Loan Agreement includes certain limited representations and warranties and negative covenants of the Company. An event of default under the Loan Agreement includes, among other things, (i) the Company breaches its obligations under the Loan Agreement, and where that breach is capable of remedy it does not remedy the breach within 20 business days after receipt of a notice from the Mayne Pharma of the breach, (ii) Mayne Pharma validly terminates the Third Amended and Restated Supply and License Agreement dated December 17, 2018 between the Company and Mayne Pharma, or (iii) the Company becomes insolvent, including by becoming the subject of the filing or institution of bankruptcy, liquidation or dissolution proceedings. The Loan Agreement was negotiated and approved on behalf of the Company by a special committee of disinterested, independent members of the Company’s Board of Directors (the “Board”) which was formed on November 17, 2020 for such purpose. The special Board committee consisted of W. Mark Watson, R. Dana Ono and Debra Peattie, who are each disinterested with respect to Mayne Pharma. On January 13, 2022, the Company executed a letter agreement with Mayne Pharma to amend the Loan Agreement and the Facility (the “Loan Amendment”). Under the terms of the Loan Amendment: (i) amount of the facility was increased by $50,000 to $281,000, (ii) the maturity date of the Facility was extended to December 31, 2022, (iii) such $50,000 increase will be available for draw down from February 1, 2022 until March 31, 2022 in no less than $25,000 increments, (iv) following March 31, 2022, the outstanding amount under the Facility plus interest thereon will be amortized over equal monthly payments through the maturity date and (v) the parties acknowledged that the full $231,000 under the original Facility had been drawn down by the Company. Except as modified by the Loan Amendment, the terms and conditions of the Loan Agreement and the Facility remain in full force and effect. The proceeds of the expanded Facility will be used by the Company for general working capital purposes, including the payment of a portion of previously deferred employee compensation. Proceeds of $50,000 related to this letter agreement were received during the quarter ended March 31, 2022. On March 9, 2022, the Company executed an additional letter agreement with Mayne Pharma to amend the Loan Agreement and the Facility (the “Second Loan Amendment”). Under the terms of the Second Loan Amendment: (i) amount of the Facility was increased by $50,000 to $331,000, (ii) such $50,000 increase will be available for draw down from April 1, 2022 until May 31, 2022 in no less than $25,000 increments, (iv) following May 31, 2022, the outstanding amount under the Facility plus interest thereon will be amortized over equal monthly payments through the maturity date and (v) the parties acknowledged that the full $281,000 under the original Facility had been drawn down by the Company. Except as modified by the Second Loan Amendment, the terms and conditions of the Loan Agreement and the Facility remain in full force and effect. The proceeds of the expanded Facility will be used by us for general working capital purposes, including the payment of a portion of previously deferred employee compensation. Proceeds of $50,000 related to this letter agreement were received in April 2022. On July 13 was provided by Mayne Pharma under the Loan Agreement, which proceeds are anticipated to allow the Company to continue its current state of operations into October 2022.

Stockholders' Equity_

Stockholders' Equity:	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity [Abstract]
Stockholders' Equity	6. Stockholders’ Equity: Employee Stock Plans There was no stock-based compensation for the six months ended June 30, 2022. As of June 30, 2022, there were 13,349,461 outstanding common stock options under the EIP of which 100% were vested. There was no unamortized stock-based compensation at June 30, 2022.

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	7. Legal Proceedings: The Company may from time to time become a party to various legal proceedings arising in the ordinary course of business. Except as discussed below, the Company is not the subject of any pending legal proceedings. On July 9, 2019, Hedgepath, LLC (“HPLLC”), a significant minority stockholder of the Company and an investment vehicle associated with the Company’s former Executive Chairman, filed a civil action captioned Hedgepath, LLC v. Magrab, et al. Number 2019-0529-JTL, On December 3, 2019, HPLLC filed the Verified Amended and Supplemental Complaint. In the Complaint in the Action, purportedly brought directly and derivatively on behalf of the Company, HPLLC alleges claims for breach of fiduciary duty, declaratory judgement, and dilution of stockholder equity, against the Individual Defendants and Mayne Pharma in connection with (i) the previously announced issuance of certain Company equity securities to Mayne Pharma on or about January 8, 2018, (ii) Mayne Pharma’s alleged influence over the timing and conduct of the previous clinical trial of SUBA-Itraconazole for the treatment of BCCNS, and (iii) previously announced amendments to the Supply and License Agreement, as amended (presently memorialized at the Third Amended SLA), between the Company and Mayne Pharma and certain transactions contemplated thereby. The Complaint also alleges claims for breach of fiduciary duty and fraudulent misrepresentation in connection with allegedly false and misleading statements included in Company press releases and filings with the SEC. The Complaint seeks unspecified damages, equitable and other relief from the defendants. Legal costs associated directly with the Company as a nominal defendant were initially payable by the Company until certain retention amounts were reached. Such costs are currently covered by the Company’s insurance policy. On January 10, 2020, the Individual Defendants and Mayne Pharma each filed a motion to dismiss the Complaint. A hearing on those motions was scheduled on March 26, 2020, but was postponed to June 2020 due to the coronavirus outbreak. On June 4, 2020, the Delaware Court of Chancery held a hearing at which the separate motions of the Individual Defendants and Mayne Pharma to dismiss the Complaint were presented. At the conclusion of the hearing, the Court issued an oral ruling in which it denied the motions and declined to dismiss all counts alleged in the Complaint. Accordingly, the Action has been proceeding in the course typical for such litigation, which could include alternative dispute resolution methods. The Company believes the Action is legally and factually baseless, and the Individual Defendants intend to defend themselves vigorously. Additionally, on March 23, 2020, a Stockholder Class Action Complaint was filed in the Delaware Court of Chancery by a Company stockholder and purported class representative Samuel P. Sears, commencing litigation captioned Sears v. Magrab et al., C.A. No. 2020-0215-JTL claims-one Defendants-and The Company believes the Putative Class Action is legally and factually baseless, and the Individual Defendants intend to defend themselves vigorously.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Estimates	Estimates The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition The Company currently has no ongoing source of revenues. Miscellaneous income, including interest, is recognized when earned by the Company. Deferred revenue represents cash received for royalties in advance of being earned. Such payments are reflected as deferred revenue until recognized under the Company’s revenue recognition policy. Deferred revenue would be classified as current if management believes the Company will be able to recognize the deferred amount as revenue within twelve months of the balance sheet date. Deferred revenue will be recognized when the product is sold and the royalty is earned. Since all deferred revenue is related to the SUBA-Itraconazole BCCNS product which is yet to be approved by FDA, the Company has determined that 100% of the advances of the royalty received by Mayne Pharma should be classified as non-current.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts which is $250,000 for substantially all depository accounts. As of June 30, 2022, the Company had no excess of the amount covered by Federal Deposit Insurance Corporation.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company and purchased in-process
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employees
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. These differences occur primarily in share-based compensation.
Recent accounting pronouncements	Recent accounting pronouncements: Management has considered all recent accounting pronouncements issued, but not effective, and does not believe that they will have a material impact on the Company’s financial statements.

Corporate Overview - Additional

Corporate Overview - Additional Information (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
Royalty rate on future net sales	9%

Liquidity and Management's Pl_2

Liquidity and Management's Plans - Additional Information (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Cash and cash equivalents [Line Items]
Cash and cash equivalents	$ 24,945	$ 30,626

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Line Items]
Cash, FDIC insured amount	$ 250,000
Royalty [Member]
Accounting Policies [Line Items]
Deferred revenue	$ 3,000,000	$ 3,000,000

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - USD ($)			6 Months Ended
	May 03, 2020	May 02, 2020	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Long Term Notes Payable [Line Items]
Proceeds from notes payable			$ 100,000	$ 176,000
Citibank [Member] | Paycheck Protection Program Loan [Member]
Disclosure Of Long Term Notes Payable [Line Items]
Proceeds from notes payable	$ 41,600
Debt instrument maturity date		May 02, 2022
Debt instrument stated interest rate		1%

Mayne Term Debt Facility - Addi

Mayne Term Debt Facility - Additional Information (Detail) - USD ($)				1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Mar. 09, 2022	Jan. 13, 2022	Dec. 12, 2020	Apr. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Jul. 13, 2022	Dec. 31, 2020	Dec. 14, 2020
Line of Credit Facility [Line Items]
Credit facility draw down amount	$ 281,000	$ 231,000
Mayne Pharma [Member]
Line of Credit Facility [Line Items]
Credit facility aggregate Credit facility			$ 231,000
Credit facility interest rate description			US Bank Prime Rate plus 5.00%
Credit facility instrument term			24 months
Credit facility amount drawn in first annual quarter										$ 81,000
Credit facility outstanding									$ 55,000
Credit facility amount drawn in second and third annual quarters							$ 75,000
Credit facility draw down payment							$ 25,000
Credit facility covenant compliance						An event of default under the Loan Agreement includes, among other things, (i) the Company breaches its obligations under the Loan Agreement, and where that breach is capable of remedy it does not remedy the breach within 20 business days after receipt of a notice from the Mayne Pharma of the breach, (ii) Mayne Pharma validly terminates the Third Amended and Restated Supply and License Agreement dated December 17, 2018 between the Company and Mayne Pharma, or (iii) the Company becomes insolvent, including by becoming the subject of the filing or institution of bankruptcy, liquidation or dissolution proceedings.
Mayne Pharma [Member] | Subsequent Event [Member]
Line of Credit Facility [Line Items]
Credit facility aggregate Credit facility								$ 40,000
Mayne Pharma [Member] | Loan Amendment [Member] | Letter Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility aggregate Credit facility	331,000	281,000
Increase in the amount of facility	$ 50,000	$ 50,000
Credit facility extended maturity date		Dec. 31, 2022
Credit facility increased facility amount draw down terms	such $50,000 increase will be available for draw down from April 1, 2022 until May 31, 2022 in no less than $25,000 increments	such $50,000 increase will be available for draw down from February 1, 2022 until March 31, 2022 in no less than $25,000 increments
ProceedsFromLinesOfCredit				$ 50,000	$ 50,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	$ 0	$ 37,990
Two Thousand Fourteen Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option outstanding under 2009 stock incentive plan	13,349,461
RSUs vesting percentage	100%
Total stock based compensation expense	$ 0
Unamortized stock-based compensation cost related to unpaid RSUs	$ 0